--- title: "Ludwig Enterprises, Inc. (LUDG.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/LUDG.US.md" symbol: "LUDG.US" name: "Ludwig Enterprises, Inc." industry: "Biotechnology" --- # Ludwig Enterprises, Inc. (LUDG.US) | Item | Detail | |------|--------| | Industry | Biotechnology | | Location | US Market | | Website | [www.ludwigent.com](https://www.ludwigent.com) | ## Company Profile Ludwig Enterprises, Inc. operates as a genomic technology and health related company in the United States. The company engages in the developing of products that use inflammatory genetic markers to assess the occurrence of inflammation and inflammation related diseases, as well as monitor treatment ... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-21T04:30:13.000Z **Overall: D (0.77)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 331 / 403 | | Industry Median | D | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -100.00% | | | Net Profit YoY | 60.28% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | -1.08 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 3.59M | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 0.00 | | **Multi Score**: D #### Profit Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 55.21% | A | | Profit Margin | 0.00% | D | | Gross Margin | 0.00% | E | #### Growth Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -100.00% | E | | Net Profit YoY | 60.28% | B | | Total Assets YoY | 91.13% | A | | Net Assets YoY | -42.16% | E | #### Cash Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 0.00% | D | | OCF YoY | -100.00% | E | #### Operating Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.00 | E | #### Debt Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 1365.67% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Ludwig Enterprises, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "B", "indicators": [ { "name": "ROE", "value": "55.21%", "rating": "A" }, { "name": "Profit Margin", "value": "0.00%", "rating": "D" }, { "name": "Gross Margin", "value": "0.00%", "rating": "E" } ] }, { "name": "Growth", "grade": "D", "indicators": [ { "name": "Revenue YoY", "value": "-100.00%", "rating": "E" }, { "name": "Net Profit YoY", "value": "60.28%", "rating": "B" }, { "name": "Total Assets YoY", "value": "91.13%", "rating": "A" }, { "name": "Net Assets YoY", "value": "-42.16%", "rating": "E" } ] }, { "name": "Cash", "grade": "E", "indicators": [ { "name": "Cash Flow Margin", "value": "0.00%", "rating": "D" }, { "name": "OCF YoY", "value": "-100.00%", "rating": "E" } ] }, { "name": "Operating", "grade": "E", "indicators": [ { "name": "Turnover", "value": "0.00", "rating": "E" } ] }, { "name": "Security", "grade": "E", "indicators": [ { "name": "Gearing Ratio", "value": "1365.67%", "rating": "E" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A | | 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A | | 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A | | 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A | | 05 | OpGen (US.OPGN) | B | A | A | A | B | A | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -2.73 | 290/604 | - | - | - | | PB | -1.08 | 491/604 | - | - | - | | PS (TTM) | 42605.86 | - | 71418.54 | 48205.48 | 41290.06 | | Dividend Yield | 0.00% | - | - | - | - | ## References - [Company Overview](https://longbridge.com/en/quote/LUDG.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/LUDG.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/LUDG.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.